← Back to Screener
Hoth Therapeutics, Inc. Common Stock (HOTH)
Price$1.97
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)16.87%
Price vs S&P 500 (4W)125.35%
VGM Score84.27
Market Capitalization$30.69M
All Metrics
Book Value / Share (Quarterly)$0.26
P/TBV (Annual)0.94x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.64
Price vs S&P 500 (YTD)44.37%
EPS (TTM)$-0.81
10-Day Avg Trading Volume36.73M
EPS Excl Extra (TTM)$-0.81
EPS (Annual)$-0.90
ROI (Annual)-202.73%
Cash / Share (Quarterly)$0.25
ROA (Last FY)-164.00%
EBITD / Share (TTM)$-0.79
ROE (5Y Avg)-155.54%
Cash Flow / Share (Annual)$-0.65
P/B Ratio7.38x
P/B Ratio (Quarterly)3.29x
Net Income / Employee (Annual)$-6,234,700
Net Interest Coverage (TTM)-114.51x
ROA (TTM)-143.61%
EPS Incl Extra (Annual)$-0.90
Current Ratio (Annual)4.72x
Quick Ratio (Quarterly)2.87x
3-Month Avg Trading Volume6.06M
52-Week Price Return24.79%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.42
52-Week High$2.45
EPS Excl Extra (Annual)$-0.90
CapEx CAGR (5Y)12.03%
Tangible BV CAGR (5Y)34.02%
26-Week Price Return24.79%
Quick Ratio (Annual)4.47x
13-Week Price Return49.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.39x
Enterprise Value$26.65M
Book Value / Share Growth (5Y)-45.95%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.40
3-Month Return Std Dev259.21%
Net Income / Employee (TTM)$-5,843,000
ROE (Last FY)-202.73%
Net Interest Coverage (Annual)-61.28x
EPS Basic Excl Extra (Annual)$-0.90
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.81
ROI (TTM)-165.25%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.93
Price vs S&P 500 (52W)0.43%
Year-to-Date Return52.53%
5-Day Price Return12.69%
EPS Normalized (Annual)$-0.90
ROA (5Y Avg)-130.20%
Month-to-Date Return3.42%
EBITD / Share (Annual)$-0.90
ROI (5Y Avg)-155.54%
EPS Basic Excl Extra (TTM)$-0.81
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)2.50x
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)41.25%
Beta0.80x
Revenue / Share (TTM)$0.00
ROE (TTM)-165.25%
52-Week Low$0.49
mGradeA
vgmGradeA
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HOTHHoth Therapeutics, Inc. Common Stock | — | — | A | $1.97 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies across oncology, immunology, neurology, and dermatology. Its pipeline includes treatments for cancer treatment side effects (HT-001), mast cell cancers and anaphylaxis (HT-KIT), Alzheimer's disease (HT-ALZ), atopic dermatitis (BioLexa), asthma and allergies (HT-004), and obesity (HT-VA). The company focuses on areas with significant unmet medical needs.